In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
- PMID: 35226528
- DOI: 10.7326/J22-0003
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
Abstract
Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650. 34693515.
Comment on
- 
  
  Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2. Cochrane Database Syst Rev. 2021. PMID: 34693515 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        